Sindhuvallathy mezhugu ( SVM)

PreclinicalSmall molecule

Sindhuvallathy mezhugu ( SVM) is one of 4 small molecule programs targeting Kidney Stones. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney StonesCompleted

Kidney StonesPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Kidney Stones

#DrugCompanyPhaseTrials

Thalitone

Jazz Pharmaceuticals

Approved

1 2

Potassium Iodide

MMeda Pharmaceuticals

Approved

2 3

Alka-Seltzer

AAbbott

Phase 2

1 4

Sindhuvallathy mezhugu ( SVM)

TTamil Nadu Dr.M.G.R.Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Stones1 trial

A Clinical Study to Evaluate the Efficacy of Two Siddha Drugs Sindhuvallathy Mezhugu and Kalladaippu Kudineer for Kidney Stones

Completed·TTamil Nadu Dr.M.G.R.Medical University·N/A·NCT01847963·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sindhuvallathy mezhugu ( SVM). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sindhuvallathy mezhugu ( SVM) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sindhuvallathy mezhugu ( SVM). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tamil Nadu Dr.M.G.R.Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTamil Nadu Dr.M.G.R.Medical University

Sindhuvallathy mezhugu ( SVM)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Stones1 trial

References

Drug Info

Quick Facts

Related News